RxDoctor Payments Data

John Hoyt, MD

Interventional Cardiology · Bismarck, NDNPI 1194929182

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $445, 4.3 times the $103 reported in 2019.

$1,109in general payments, 2019–2025

Across 44 payments — averaging $25.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$195
  • Abiomed$177
  • Boston Scientific$139
  • E.r. Squibb & Sons, L.L.C.$103
  • Actelion Pharmaceuticals US, Inc.$96
  • Lantheus Medical Imaging, Inc.$64
  • plus $334 from 12 others

What the payments were for

  • Food & beverage$1,109100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few interventional cardiology providers in North Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$267,109
Medicare patients
3,685
Services billed
7,654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis16$525,238
EliquisApixaban435$358,804
EntrestoSacubitril/Valsartan205$201,981
JardianceEmpagliflozin186$187,177
XareltoRivaroxaban89$76,219
Repatha SureclickEvolocumab41$41,790
BrilintaTicagrelor18$9,790
Metoprolol Succinate483$9,596
Repatha SyringeEvolocumab11$8,682
Praluent PenAlirocumab16$7,510
Potassium Chloride177$6,223
Rosuvastatin Calcium439$6,135
Icosapent Ethyl13$5,071
Isosorbide Mononitrate ErIsosorbide Mononitrate266$4,988
Atorvastatin Calcium350$4,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$31$884,042451 claims
NovartisEntresto$35$201,981205 claims
AstraZenecaBrilinta$14$9,79018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in North Dakotaon file to place this against a meaningful peer group, so we don't.

Other interventional cardiology in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →